Skip to content
10-Q

Quarterly Report

REGENERON PHARMACEUTICALS, INC. REGN

0001804220-24-000040

← back to feed
Filed
Oct 31, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Long Term Debt Q3 2024 · Sep 30, 2024 $1.98B
Long Term Debt Q3 2024 · Dec 31, 2023 $1.98B
Current Liabilities Q3 2024 · Sep 30, 2024 $3.66B
Current Liabilities Q3 2024 · Dec 31, 2023 $3.42B
Total Liabilities Q3 2024 · Sep 30, 2024 $8.12B
Total Liabilities Q3 2024 · Dec 31, 2023 $7.11B
Current Assets Q3 2024 · Sep 30, 2024 $19.33B
Current Assets Q3 2024 · Dec 31, 2023 $19.48B
Total Assets Q3 2024 · Sep 30, 2024 $37.44B
Total Assets Q3 2024 · Dec 31, 2023 $33.08B
Cash And Equivalents Q3 2024 · Dec 31, 2023 $2.73B
Cash And Equivalents Q3 2024 · Sep 30, 2023 $2.15B
Shares Diluted Q3 2024 · Sep 30, 2023 113.4M sh
Shares Diluted Q3 2024 · Sep 30, 2023 113.7M sh
Stock Repurchased Q3 2024 · Sep 30, 2023 $1.95B
Capex Q3 2024 · Sep 30, 2023 $467.2M
Operating Cash Flow Q3 2024 · Sep 30, 2023 $3.5B
Stockholders Equity Q3 2024 · Sep 30, 2023 $24.9B
Stockholders Equity Q3 2024 · Jun 30, 2023 $24.02B
Stockholders Equity Q3 2024 · Mar 31, 2023 $23.5B
Stockholders Equity Q3 2024 · Dec 31, 2022 $22.66B
Eps Diluted Q3 2024 · Sep 30, 2023 $8.89
Eps Diluted Q3 2024 · Sep 30, 2023 $24.57
Eps Basic Q3 2024 · Sep 30, 2023 $9.48
Eps Basic Q3 2024 · Sep 30, 2023 $26.16
Sga Expense Q3 2024 · Sep 30, 2023 $640.5M
Sga Expense Q3 2024 · Sep 30, 2023 $1.89B
Rd Expense Q3 2024 · Sep 30, 2023 $1.08B
Rd Expense Q3 2024 · Sep 30, 2023 $3.26B
Net Income Q3 2024 · Sep 30, 2023 $1.01B
Net Income Q3 2024 · Sep 30, 2023 $2.79B
Net Income Q3 2024 · Jun 30, 2023 $968.4M
Net Income Q3 2024 · Mar 31, 2023 $817.8M
Operating Income Q3 2024 · Sep 30, 2023 $1.11B
Operating Income Q3 2024 · Sep 30, 2023 $3.07B
Revenue Q3 2024 · Sep 30, 2023 $3.36B
Revenue Q3 2024 · Sep 30, 2023 $9.68B